Impact of a multi-strain L. crispatus-based vaginal synbiotic on the vaginal microbiome: a randomized placebo-controlled trial
Jacques Ravel, Sheri L. Simmons, Eleni A. Greenwood, Sara Gottfried, Miriam Greene, Susan Kellogg‐Spadt, Dirk Gevers, Diane M. Harper
Abstract
A clinical trial of a multi-strain vaginal synbiotic (NCT05659745, registered 12/19/2022 at clinicaltrials.gov) led to an optimal vaginal microbiome dominated by L. crispatus (CST I). The synbiotic led to a significant increase in L. crispatus compared to placebo (p < 0.05), and conversion to CST I was significantly higher with the vaginal synbiotic than with placebo (90 vs 11%; p < 0.002). Mechanistically, the synbiotic reduced Gardnerella vaginalis and Candida, clinically important microbes.
Topics & Concepts
Lactobacillus crispatusPlaceboGardnerella vaginalisMicrobiomeBacterial vaginosisInternal medicineMedicineMicrobiologyGynecologyBiologyLactobacillusFood scienceBioinformaticsPathologyFermentationAlternative medicineReproductive tract infections researchUrinary Tract Infections ManagementPelvic floor disorders treatments